Foghorn Therapeutics is a clinical-stage precision biotechnology company developing small-molecule medicines targeting the chromatin regulatory system, which controls gene expression and is mutated in approximately half of all cancers. The company uses its proprietary Gene Traffic Control platform—combining genomic screening, AI/machine learning, and high-throughput testing—to identify and validate drug targets and advance a pipeline of over seven programs across enzyme inhibitors, protein degraders, and transcription factor disruptors, initially in oncology with potential expansion to immunology and inflammatory diseases. Foghorn generates revenue through a strategic collaboration with Eli Lilly that includes upfront payments, equity investment, co-commercialization economics on the lead SMARCA2 program in the United States, tiered royalties on international sales, and potential milestone payments totaling up to $1.3 billion, while the company retains rights to participate in U.S. co-development and domestically-focused commercialization alongside Lilly's global development efforts.